Recombinant human interleukin-1 receptor type I in the treatment of patients with active rheumatoid arthritis

Keyphrases

• Recombinant Human 100%
• Active Rheumatoid Arthritis 100%
• Interleukin-1 Receptor Type I 100%
• Recombinant 90%
• Placebo 20%
• Cell Surface 20%
• Interleukin-1β 20%
• Monocytes 20%
• Clinically Significant 20%
• High Concentration 20%
• Flow Cytometry 10%
• Inflammatory Cells 10%
• Phenotypic Characteristics 10%
• Peripheral Blood 10%
• Randomized Double-blind 10%
• Rash 10%
• Adverse Events 10%
• Consecutive Days 10%
• Small Dose 10%
• Disease Activity 10%
• Dose-limiting Toxicity 10%
• Phase I Study 10%
• Distribution Characteristics 10%
• Laboratory Assessment 10%
• Swollen Joint 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Rheumatoid Arthritis 100%
• Interleukin 1 Receptor Type I 100%
• Inflammatory Arthritis 100%
• Placebo 20%
• Adverse Event 10%
• Flow Cytometry 10%
• Rash 10%
• Subcutaneous Injection 10%
• Disease Activity 10%
• Immunoreactive Insulin 10%

Immunology and Microbiology

• Inflammatory Arthritis 100%
• Interleukin 1 Receptor, Type I 100%
• Cell Surface 20%
• Interleukin-1 20%
• Inflammatory Cell 10%